TriSalus Life Sciences, Inc. (TLSI)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
$5.00+0.40%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · TLSI
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue expanding the commercial organization to support future growth and broader market penetration of the TriNav platform and PEDD technology.
Stated as a priority in 3 of last 3 quarters. Revenue increased from $8.9 million in 2026-Q1 to $11.4 million in 2026-Q2, reflecting commercial expansion efforts. The company maintains 2026 revenue guidance of $54 million to $57 million. The trajectory shows delivering growth aligned with management's stated commercial expansion priority.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated weak grew net income 28% of the time over the next year (vs 52% for the rest of the cohort, n=10029).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
“Expanded commercial organization to support future growth and broader market penetration”
“Significantly strengthened our commercial infrastructure and substantially completed commercial expansion initiatives”
“Continued commercial expansion initiatives designed to support long-term growth and broader market opportunity”
Obtain FDA clearance for the next-generation TriNav Advance device to extend PEDD capability to small distal vessels via microcatheter.
Stated as a priority in 2 of last 3 quarters. Management linked the timing of FDA clearance for TriNav Advance to revenue guidance revisions in 2026. No specific clearance milestone reported yet, indicating ongoing regulatory process with limited substantive delivery so far.
“Revenue guidance reflects impact of timing of FDA clearance for TriNav Advance”
“Delayed FDA clearance timing for TriNav Advance affects revenue outlook”
Focus on improving operating income by managing sales and marketing expenses and leveraging improved gross margins.
Stated as a priority in 2 of last 3 quarters. Operating losses increased from $8.4 million in 2026-Q1 to $9.8 million in 2026-Q2 despite gross margin improvement from 86.2% to 86.8%. Increased sales and marketing expenses offset margin gains, indicating limited progress on improving operating income so far.
“Operating losses increased due to higher sales and marketing expenses partially offset by improved gross margins”
“Operating losses increased driven by higher sales and marketing expenses and stock-based compensation, partially offset by improved gross margins”
Generate and publish clinical and preclinical data to validate the value and expand applications of the PEDD drug delivery technology.
Stated as a priority in 2 of last 3 quarters. Management reported publication of a large real-world PEDD study and new clinical/preclinical data presentations supporting PEDD's value and expanded applications. This reflects delivering on clinical evidence generation as a strategic priority.
“Hosted virtual KOL event and submitted PEDIR study data for publication supporting PEDD in liver cancer”
“Published landmark real-world PEDD study and presented new clinical and preclinical data at scientific meeting”
Ensure adequate liquidity through equity offerings and cash management to fund commercial growth and clinical pipeline advancement.
Stated as a priority in 2 of last 3 quarters. The company raised $46 million in gross proceeds in 2026-Q1, with cash and cash equivalents decreasing from $56.6 million in 2026-Q1 to $46.3 million in 2026-Q2. Management affirms sufficient cash runway to fund commercial expansion and pipeline development, indicating delivering liquidity management.
“Cash and cash equivalents totaled $46.3 million; proceeds provide sufficient runway to fund commercial expansion and pipeline development”
“Raised $46 million in gross proceeds from equity offering; cash balance of $56.6 million fully funds commercial expansion and pipeline development”
Over the trailing year it converted 0.54x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, Fed net liquidity, long-term interest rates, real (inflation-adjusted) rates (low R² over the window).
17 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.